39539628|t|Riluzole attenuates acute neural injury and reactive gliosis, hippocampal-dependent cognitive impairments and spontaneous recurrent generalized seizures in a rat model of temporal lobe epilepsy.
39539628|a|Background: Riluzole exhibits neuroprotective and therapeutic effects in several neurological disease models associated with excessive synaptic glutamate (Glu) release. We recently showed riluzole prevents acute excitotoxic hippocampal neural injury at 3 days in the kainic acid (KA) model of temporal lobe epilepsy (TLE). Currently, it is unknown if preventing acute neural injury and the neuroinflammatory response is sufficient to suppress epileptogenesis. Methods: The KA rat model of TLE was used to determine if riluzole attenuates acute hippocampal neural injury and reactive gliosis. KA was administered to adult male Sprague-Dawley (250 g) rats at 5 mg/kg/hr until status epilepticus (SE) was observed, and riluzole was administered at 10 mg/kg 1 h and 4 h after SE and once per day for the next 2 days. Immunostaining was used to assess neural injury (FJC and NeuN), microglial activation (Iba1 and ED-1/CD68) and astrogliosis (GFAP and vimentin) at day 7 and day 14 after KA-induced SE. Learning and memory tests (Y-maze, Novel object recognition test, Barnes maze), behavioral hyperexcitability tests, and spontaneous generalized recurrent seizure (SRS) activity (24-hour video monitoring) were assessed at 11-15 weeks. Results: Here we show that KA-induced hippocampal neural injury precedes the neuroimmune response and that riluzole attenuates acute neural injury, microglial activation, and astrogliosis at 7 and 14 days. We find that reducing acute hippocampal injury and the associated neuroimmune response following KA-induced SE by riluzole attenuates hippocampal-dependent cognitive impairment, behavioral hyperexcitability, and tonic/clonic generalized SRS activity after 3 months. We also show that riluzole attenuates SE-associated body weight loss during the first week after KA-induced SE. Discussion: Riluzole acts on multiple targets that are involved to prevent excessive synaptic Glu transmission and excitotoxic neuronal injury. Attenuating KA-induced neural injury and subsequent microglia/astrocyte activation in the hippocampus and extralimbic regions with riluzole reduces TLE-associated cognitive deficits and generalized SRS and suggests that riluzole could be a potential antiepileptogenic drug.
39539628	0	8	Riluzole	Chemical	MESH:D019782
39539628	26	39	neural injury	Disease	MESH:D014947
39539628	53	60	gliosis	Disease	MESH:D005911
39539628	62	73	hippocampal	Disease	MESH:D000092223
39539628	84	105	cognitive impairments	Disease	MESH:D003072
39539628	144	152	seizures	Disease	MESH:D012640
39539628	158	161	rat	Species	10116
39539628	171	193	temporal lobe epilepsy	Disease	MESH:D004833
39539628	207	215	Riluzole	Chemical	MESH:D019782
39539628	276	296	neurological disease	Disease	MESH:D020271
39539628	339	348	glutamate	Chemical	MESH:D018698
39539628	350	353	Glu	Chemical	MESH:D018698
39539628	383	391	riluzole	Chemical	MESH:D019782
39539628	419	444	hippocampal neural injury	Disease	MESH:D001930
39539628	462	473	kainic acid	Chemical	MESH:D007608
39539628	475	477	KA	Chemical	MESH:D007608
39539628	488	510	temporal lobe epilepsy	Disease	MESH:D004833
39539628	512	515	TLE	Disease	MESH:D004833
39539628	563	576	neural injury	Disease	MESH:D014947
39539628	585	602	neuroinflammatory	Disease	MESH:D000090862
39539628	668	670	KA	Chemical	MESH:D007608
39539628	671	674	rat	Species	10116
39539628	684	687	TLE	Disease	MESH:D004833
39539628	713	721	riluzole	Chemical	MESH:D019782
39539628	739	764	hippocampal neural injury	Disease	MESH:D001930
39539628	778	785	gliosis	Disease	MESH:D005911
39539628	787	789	KA	Chemical	MESH:D007608
39539628	844	848	rats	Species	10116
39539628	869	887	status epilepticus	Disease	MESH:D013226
39539628	889	891	SE	Disease	MESH:D013226
39539628	911	919	riluzole	Chemical	MESH:D019782
39539628	967	969	SE	Disease	MESH:D013226
39539628	1042	1055	neural injury	Disease	MESH:D014947
39539628	1065	1069	NeuN	Gene	287847
39539628	1095	1099	Iba1	Gene	29427
39539628	1109	1113	CD68	Gene	287435
39539628	1119	1131	astrogliosis	Disease	MESH:D005911
39539628	1133	1137	GFAP	Gene	24387
39539628	1142	1150	vimentin	Gene	81818
39539628	1178	1180	KA	Chemical	MESH:D007608
39539628	1189	1191	SE	Disease	MESH:D013226
39539628	1284	1301	hyperexcitability	Disease	
39539628	1337	1354	recurrent seizure	Disease	MESH:D012008
39539628	1356	1359	SRS	Disease	OMIM:614389
39539628	1454	1456	KA	Chemical	MESH:D007608
39539628	1465	1490	hippocampal neural injury	Disease	MESH:D001930
39539628	1534	1542	riluzole	Chemical	MESH:D019782
39539628	1560	1573	neural injury	Disease	MESH:D014947
39539628	1602	1614	astrogliosis	Disease	MESH:D005911
39539628	1661	1679	hippocampal injury	Disease	MESH:D001930
39539628	1730	1732	KA	Chemical	MESH:D007608
39539628	1741	1743	SE	Disease	MESH:D013226
39539628	1747	1755	riluzole	Chemical	MESH:D019782
39539628	1767	1778	hippocampal	Disease	MESH:D000092223
39539628	1789	1809	cognitive impairment	Disease	MESH:D003072
39539628	1822	1839	hyperexcitability	Disease	
39539628	1845	1857	tonic/clonic	Disease	MESH:D004830
39539628	1870	1873	SRS	Disease	OMIM:614389
39539628	1917	1925	riluzole	Chemical	MESH:D019782
39539628	1937	1939	SE	Disease	MESH:D013226
39539628	1956	1967	weight loss	Disease	MESH:D015431
39539628	1996	1998	KA	Chemical	MESH:D007608
39539628	2007	2009	SE	Disease	MESH:D013226
39539628	2023	2031	Riluzole	Chemical	MESH:D019782
39539628	2105	2108	Glu	Chemical	MESH:D018698
39539628	2126	2153	excitotoxic neuronal injury	Disease	MESH:D009410
39539628	2167	2169	KA	Chemical	MESH:D007608
39539628	2178	2191	neural injury	Disease	MESH:D014947
39539628	2286	2294	riluzole	Chemical	MESH:D019782
39539628	2303	2306	TLE	Disease	MESH:D004833
39539628	2318	2336	cognitive deficits	Disease	MESH:D003072
39539628	2353	2356	SRS	Disease	OMIM:614389
39539628	2375	2383	riluzole	Chemical	MESH:D019782
39539628	Negative_Correlation	MESH:D019782	MESH:D015431
39539628	Negative_Correlation	MESH:D019782	MESH:D013226
39539628	Negative_Correlation	MESH:D019782	MESH:D012640
39539628	Positive_Correlation	MESH:D007608	MESH:D004833
39539628	Negative_Correlation	MESH:D007608	MESH:D019782
39539628	Association	MESH:D005911	24387
39539628	Positive_Correlation	MESH:D007608	MESH:D004830
39539628	Negative_Correlation	MESH:D019782	MESH:D004830
39539628	Positive_Correlation	MESH:D018698	MESH:D019782
39539628	Negative_Correlation	MESH:D019782	MESH:D003072
39539628	Negative_Correlation	MESH:D019782	MESH:D005911
39539628	Positive_Correlation	MESH:D007608	MESH:D000092223
39539628	Association	MESH:D005911	81818
39539628	Positive_Correlation	MESH:D007608	MESH:D014947
39539628	Positive_Correlation	MESH:D007608	MESH:D001930
39539628	Negative_Correlation	MESH:D019782	MESH:D000092223
39539628	Positive_Correlation	MESH:D007608	MESH:D003072
39539628	Positive_Correlation	MESH:D007608	OMIM:614389
39539628	Negative_Correlation	MESH:D019782	MESH:D004833
39539628	Positive_Correlation	MESH:D007608	MESH:D013226
39539628	Negative_Correlation	MESH:D019782	MESH:D001930
39539628	Negative_Correlation	MESH:D019782	OMIM:614389
39539628	Negative_Correlation	MESH:D019782	MESH:D014947

